Buy Ceclor (Cefaclor) Online — Second-Generation Cephalosporin Antibiotic for Otitis Media, Sinusitis & Respiratory Infections

Ceclor is the original brand name of cefaclor, a second-generation oral cephalosporin antibiotic developed and originally marketed by Eli Lilly. Ceclor received FDA approval in 1979 and has been in continuous global clinical use for more than four decades. The drug is now also widely available as generic cefaclor from numerous manufacturers worldwide and as the extended-release formulation Ceclor CD (approved 1996).

Within the cephalosporin family, cefaclor occupies a specific niche as a second-generation oral agent with broader gram-negative coverage than the first-generation cephalosporins (cephalexin, cefadroxil) while retaining adequate gram-positive activity. The drug has been particularly valuable historically in pediatric otitis media, sinusitis, and pharyngitis as an alternative to first-line amoxicillin or for penicillin-allergic patients.

💊 Drug class

Second-generation oral cephalosporin (beta-lactam antibiotic); bactericidal via inhibition of bacterial cell wall synthesis through penicillin-binding protein (PBP) binding.

🏢 Original manufacturer

Ceclor originally developed and marketed by Eli Lilly (US-based pharmaceutical company); generic cefaclor now available from numerous manufacturers globally including Sandoz, Teva, Mylan, Sun Pharma, Cipla.

🌍 International brand names

Ceclor (US, Canada, EU, most markets); Ceclor CD (extended-release); Distaclor (UK); Panoral; Keflor; multiple regional names. Generic cefaclor available worldwide.

📜 FDA approval

Ceclor capsules and suspension: NDA 050521 (1979); Ceclor CD extended-release: NDA 050674 (1996); multiple generic cefaclor approvals since the 1990s.

📏 Available strengths

Immediate-release capsules: 250 mg and 500 mg. Extended-release tablets (Ceclor CD): 375 mg and 500 mg. Oral suspension: 125 mg, 187 mg, 250 mg, and 375 mg per 5 mL.

⏱️ Half-life

Approximately 0.6-0.9 hours (very short). Supports three-times-daily dosing for immediate-release formulation; the extended-release Ceclor CD supports twice-daily dosing.

🌎 WHO Essential Medicines status

Cephalosporins are included on the WHO Essential Medicines List in the Access tier of the AWaRe categorisation, indicating priority antibiotics for first-line use across common community infections.

The distinguishing features of Ceclor among contemporary antibiotics include its second-generation cephalosporin spectrum (better gram-negative than first-generation while retaining gram-positive), pediatric-friendly oral suspension formulations across multiple strengths, extensive established safety record from over four decades of clinical use, the distinctive serum sickness-like reaction profile that distinguishes cefaclor from other cephalosporins, and the availability of both immediate-release and extended-release Ceclor CD formulations.

The contemporary positioning of Ceclor is as a second-line or alternative option for community-acquired bacterial infections - amoxicillin or amoxicillin-clavulanate is typically first-line for most pediatric otitis media, sinusitis, and pharyngitis indications, with Ceclor reserved for penicillin-allergic patients, treatment failures, or where the broader gram-negative coverage of a second-generation cephalosporin is preferred. The research foundation includes pivotal pediatric clinical trials by Stan Block and colleagues on AOM, Michael Pichichero meta-analyses on cephalosporin pharyngitis therapy, and the substantial AAP and IDSA guideline framework that positions cefaclor within the broader antibiotic decision algorithm.

The development of cefaclor (Ceclor) by Eli Lilly in the 1970s was part of the broader cephalosporin family expansion that transformed antibiotic therapy in the second half of the twentieth century. The original cephalosporin compound was discovered by Giuseppe Brotzu at the University of Cagliari in Sardinia in 1948 from the fungus Cephalosporium acremonium isolated near a sewage outflow. Subsequent decades of pharmaceutical chemistry produced successive generations of cephalosporins with progressively improved spectrum and pharmacokinetics.

The second-generation cephalosporin development in the 1970s aimed to extend the gram-negative coverage of the first-generation agents (cephalexin, cephalothin) while retaining their gram-positive activity. The structural modifications focused on the side chains attached to the cephalosporin nucleus to improve beta-lactamase stability and broaden bacterial spectrum. Cefaclor (Eli Lilly), cefuroxime (Glaxo), cefprozil (Bristol-Myers Squibb), and cefoxitin (Merck) all emerged from this generation.

Timeline of cefaclor development:

The commercial heritage of Ceclor traces from Eli Lilly through to current global generic dominance. Eli Lilly retained brand-name rights for many years; generic competition since the 1990s has substantially reduced brand share. The cefaclor active ingredient is identical across brand and generic versions; FDA-approved generics are interchangeable with brand Ceclor.

The contemporary role of cefaclor reflects its specific clinical position: a useful second-line oral cephalosporin for community infections with established pediatric experience and a long safety record. The rise of amoxicillin-clavulanate (Augmentin) for many traditional cefaclor indications, and the broader stewardship trend toward narrower-spectrum first-line agents (amoxicillin) where appropriate, has restricted cefaclor empirical use somewhat. However, the drug retains meaningful clinical value for penicillin-allergic patients, treatment failures, and specific clinical scenarios where its second-generation profile is preferred.

Cefaclor (Ceclor) is a beta-lactam antibiotic that exerts its bactericidal effect through inhibition of bacterial cell wall synthesis. The mechanism is fundamentally identical to other beta-lactam antibiotics (penicillins, all cephalosporins, carbapenems, monobactams): the drug binds to bacterial enzymes called penicillin-binding proteins (PBPs) that normally synthesise peptidoglycan, the structural component of bacterial cell walls. When PBPs are inhibited, the bacterial cell wall cannot be properly formed or maintained, and the bacterium dies through osmotic lysis.

Mechanism details:

🧬 PBP binding

Cefaclor binds preferentially to specific PBPs (PBP-1, PBP-3, others depending on the bacterial species). Different PBPs perform different functions in cell wall synthesis - blocking them produces different effects on bacterial cell morphology and survival.

💥 Cell wall synthesis disruption

PBPs catalyse the transpeptidation reaction that crosslinks peptidoglycan strands forming the cell wall. With PBPs inhibited, peptidoglycan synthesis is incomplete, the cell wall is weakened, and the bacterium becomes osmotically vulnerable.

💧 Bacterial autolysis

Many susceptible bacteria activate their own autolytic enzymes when stressed by cell wall synthesis inhibition. The combination of weakened wall and autolysis produces rapid bactericidal effect within hours of adequate drug exposure.

🏛️ Selectivity for bacterial PBPs

Human cells do not have peptidoglycan cell walls or PBPs. Cefaclor binds only bacterial targets, providing therapeutic selectivity with minimal direct host cell toxicity.

🔍 Beta-lactamase considerations

Some bacteria produce beta-lactamases - enzymes that hydrolyse the beta-lactam ring of cephalosporins and inactivate them. Cefaclor has moderate beta-lactamase stability compared to first-generation cephalosporins, providing some but not complete protection against beta-lactamase-producing organisms. This is one of the principal limitations of cefaclor activity against beta-lactamase-positive H. influenzae and other gram-negative organisms.

Time-above-MIC pharmacodynamic principle:

Practical pharmacodynamic implications for cefaclor dosing:

• The short half-life (0.6-0.9 hours) of cefaclor means concentrations decline rapidly between doses
• Three-times-daily (every 8 hours) dosing of immediate-release maintains adequate time-above-MIC for typical susceptible respiratory pathogens
• Twice-daily dosing of Ceclor CD extended-release provides sustained release that maintains time-above-MIC over the 12-hour interval
• Missing doses creates significant gaps where concentrations drop below MIC, reducing antibacterial pressure
• Adherence to scheduled dosing is particularly important for short-half-life beta-lactams like cefaclor

The practical clinical message from the mechanism is that cefaclor is a true beta-lactam antibiotic with all the strengths and limitations of the class: bactericidal effect against susceptible organisms, no activity against organisms with significant beta-lactamase production (without inhibitor) or altered PBPs, time-above-MIC pharmacodynamic requirements, and the standard beta-lactam safety profile including hypersensitivity reactions.

Cephalosporin antibiotics are organised into five generations based on their introduction timeline and antibacterial spectrum. The generations reflect progressive development of agents with broader gram-negative coverage and improved beta-lactamase stability, while sometimes sacrificing some gram-positive activity. Understanding where cefaclor fits in this classification clarifies its clinical positioning relative to other cephalosporins available to prescribers.

The cephalosporin generations:

Practical clinical positioning of generations:

• First-generation oral (cephalexin): SSTI, uncomplicated UTI, surgical prophylaxis
• Second-generation oral (cefaclor, cefuroxime axetil, cefprozil): respiratory infections (otitis media, sinusitis, bronchitis), selected SSTI - where amoxicillin is unsuitable
• Third-generation oral (cefixime, cefpodoxime, cefdinir): more severe community infections, pediatric AOM treatment failures, complicated UTI in selected cases
• IV cephalosporins (ceftriaxone third-gen, cefepime fourth-gen, ceftaroline fifth-gen): hospital and severe community infections

The generation classification is a useful shorthand but not absolute - some agents have spectra that bridge generations, and individual organism susceptibility patterns matter more than generational classification for specific clinical decisions. For cefaclor specifically, the second-generation positioning means it covers most outpatient respiratory pathogens while having predictable limitations for resistant organisms (beta-lactamase-positive H. influenzae, MRSA, Pseudomonas).

The bacterial spectrum of cefaclor reflects its second-generation cephalosporin character: broader gram-negative coverage than first-generation agents while retaining gram-positive activity. Understanding the organisms cefaclor reliably covers (and those it does not) is essential for appropriate prescribing decisions.

🦠 Gram-positive cocci

Susceptible: Streptococcus pneumoniae (susceptible strains; resistance variable by region), Group A streptococcus (Streptococcus pyogenes), Group B streptococcus, methicillin-sensitive Staphylococcus aureus (MSSA), beta-hemolytic streptococci.

Resistant: Methicillin-resistant Staphylococcus aureus (MRSA) - generally resistant; Enterococcus species (intrinsic resistance to cephalosporins as a class).

🦠 Gram-negative bacilli - Enterobacterales

Susceptible: Escherichia coli (most non-ESBL strains), Klebsiella pneumoniae (susceptible strains), Proteus mirabilis, some other Enterobacterales.

Variable/Resistant: Enterobacter, Citrobacter, Serratia (AmpC beta-lactamase producers); ESBL-producing Enterobacterales; carbapenem-resistant Enterobacterales.

🦠 Respiratory gram-negative organisms

Susceptible: Haemophilus influenzae (non-beta-lactamase-producing strains; one of cefaclor strengths versus first-generation), Moraxella catarrhalis (reliable for non-beta-lactamase strains), Neisseria species.

Variable: Beta-lactamase-producing H. influenzae (cefaclor has only moderate beta-lactamase stability compared to second-generation alternatives like cefuroxime axetil).

🦠 Other gram-negative

Resistant: Pseudomonas aeruginosa (intrinsic resistance - no cephalosporin coverage until third-generation ceftazidime or fourth-generation cefepime); Acinetobacter species; Stenotrophomonas; Burkholderia.

🦠 Atypical respiratory pathogens

NOT covered: Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila - none of these are covered by cefaclor (or any beta-lactam antibiotic). If atypical coverage is needed, macrolide or doxycycline must be added.

🦠 Anaerobes

Limited activity: Some upper respiratory anaerobes (e.g., Peptostreptococcus); not reliable for serious anaerobic infections including Bacteroides fragilis abdominal infections.

🦠 Atypical mycobacteria, mycobacteria, intracellular organisms

NOT covered. Cefaclor has no significant activity against mycobacteria, Chlamydia, Mycoplasma, Rickettsia, or other intracellular pathogens.

Most clinically important organisms for routine cefaclor practice:

• Streptococcus pneumoniae - principal target for respiratory infections. Susceptibility varies by region (penicillin-non-susceptible strains often co-resistant to second-generation cephalosporins).
• Haemophilus influenzae - common respiratory pathogen. Cefaclor reliable for non-beta-lactamase strains; less reliable for beta-lactamase-positive isolates.
• Moraxella catarrhalis - common upper respiratory pathogen. Reliable coverage for non-beta-lactamase strains.
• Group A streptococcus - pharyngitis pathogen. Universally susceptible to cefaclor (and all cephalosporins).
• MSSA - common SSTI pathogen. Reliable cefaclor coverage; MRSA NOT covered.
• E. coli (susceptible strains) - common uncomplicated UTI pathogen. Cefaclor adequate for non-ESBL strains.
• Klebsiella pneumoniae (susceptible strains) - selected respiratory and UTI infections.

Important organisms NOT covered by cefaclor:

The spectrum reliability for typical outpatient community infections varies by region. In areas with high pneumococcal penicillin/cephalosporin resistance or high beta-lactamase-positive H. influenzae rates, cefaclor empirical efficacy may be suboptimal and alternative agents (Augmentin, cefuroxime axetil) may be preferred. Local antibiogram review supports appropriate empirical selection.

Cefaclor pharmacokinetics are characterised by rapid oral absorption, short half-life, predominantly renal elimination, and minimal tissue accumulation. These properties drive the standard dosing requirements (three-times-daily for immediate-release, twice-daily for Ceclor CD extended-release) and explain why renal function affects cefaclor clearance significantly.

Key pharmacokinetic parameters:

📏 Oral bioavailability

Approximately 90-95% for immediate-release cefaclor when taken on an empty stomach. Food reduces peak concentrations and slightly delays absorption but does not significantly affect total AUC. The high bioavailability is one of the practical advantages of cefaclor as an oral agent.

⏱️ Time to peak (Tmax)

Approximately 30-60 minutes for immediate-release on empty stomach. Extended-release Ceclor CD: 2-4 hours (delayed and prolonged absorption profile).

⏳ Half-life

0.6-0.9 hours - one of the shortest half-lives among oral cephalosporins. This very short half-life is the principal reason for the standard t.i.d. (every 8 hours) dosing of immediate-release cefaclor and limits the extended-release Ceclor CD to twice-daily rather than once-daily.

📊 Peak plasma concentration (Cmax)

After 500 mg oral dose immediate-release: approximately 13 mcg/mL. After 250 mg dose: approximately 7 mcg/mL. These levels exceed MICs of typical susceptible respiratory pathogens.

🧪 Protein binding

Approximately 25% (low protein binding); 75% of cefaclor in plasma is free drug available for tissue distribution and antibacterial activity.

📍 Tissue penetration

Excellent: middle ear fluid (3-5 fold plasma in selected studies), sinus mucosa, tonsillar tissue. Adequate: bronchial mucosa, skin, urinary tract. Poor: CSF (not adequate for meningitis), bone (limited).

🧬 Metabolism

Cefaclor is not significantly metabolised by the liver - approximately 60-85% is excreted unchanged in urine. The minimal hepatic metabolism means CYP450 drug interactions are not a major concern (unlike clarithromycin).

💧 Elimination

Renal: approximately 60-85% of an oral dose appears in urine as unchanged drug within 8 hours. Both glomerular filtration and tubular secretion contribute. Hepatic: minor route; approximately 10-15% via hepatic/biliary clearance.

🎯 Renal dose adjustment

Required at significant renal impairment (eCrCl below 30 mL/min). At lower clearances, half-life extends 2-3 fold and dose interval should be lengthened. See Section 18 for specific renal dosing.

Food effect on cefaclor:

Immediate-release cefaclor

Food reduces peak concentrations by approximately 25-50% and slightly delays absorption time. Total AUC is preserved. Take on empty stomach (1 hour before or 2 hours after meals) for optimal peak concentrations; or take with food if GI upset is an issue (slight peak reduction is acceptable).

Ceclor CD extended-release

Take with food - the extended-release formulation absorption is improved with food, similar to other extended-release oral antibiotics. Food increases peak concentrations and AUC compared to fasted administration.

Practical pharmacokinetic implications:

• Strict adherence to dosing schedule matters more for cefaclor than for long half-life antibiotics. Missing doses creates significant gaps in antibacterial pressure.
• Three-times-daily dosing (every 8 hours) is standard for immediate-release - typically morning, mid-day, evening with appropriate spacing.
• Twice-daily Ceclor CD provides simpler adherence pattern when indication and severity allow.
• Renal dose adjustment mandatory at eCrCl below 30 mL/min; minimal hepatic interaction concerns.
• Drug interaction profile is favorable (minimal CYP450 metabolism) compared to clarithromycin or other CYP3A4 substrates.
• Food timing: immediate-release best on empty stomach; Ceclor CD with food. Communicate this clearly at prescription.

Ceclor CD is the extended-release formulation of cefaclor, approved by FDA in 1996 (NDA 050674). The formulation provides twice-daily dosing compared to the three-times-daily immediate-release Ceclor, improving outpatient adherence for selected adult indications. Like other extended-release antibiotics, Ceclor CD has specific food requirements and tablet integrity constraints that affect appropriate prescribing.

Ceclor CD vs immediate-release Ceclor:

When to choose Ceclor CD vs immediate-release:

Common dosing for adult indications:

The practical adoption of Ceclor CD has been moderate. Twice-daily versus three-times-daily is a meaningful convenience improvement, but other competing antibiotics offer once-daily dosing (azithromycin, cefdinir, levofloxacin) or comparable convenience profiles. Generic immediate-release cefaclor remains widely used, especially in pediatric practice where the suspension formulation and capsule flexibility are valuable. Ceclor CD has a defined niche in adult outpatient respiratory infection management.

Cefaclor has a substantial list of FDA-approved indications across community-acquired bacterial infections, including respiratory tract, urinary tract, and skin and soft tissue infections. The approved indications reflect the second-generation cephalosporin spectrum and the historical clinical trial programme conducted by Eli Lilly. Understanding the full indication range supports appropriate prescribing.

FDA-approved indications for cefaclor:

Indications NOT appropriate for cefaclor:

Contemporary positioning of cefaclor:

Within the broad indication list, cefaclor occupies a specific clinical role:

• NOT typically first-line for most indications - amoxicillin or amoxicillin-clavulanate is usually preferred for respiratory infections; cephalexin for SSTI; nitrofurantoin for UTI
• Useful alternative in penicillin-allergic patients (with appropriate cephalosporin cross-reactivity assessment)
• Treatment failure scenarios where first-line agents have not worked
• Patient-specific factors favouring cephalosporin therapy (allergy patterns, prior antibiotic exposure)
• Historical pediatric AOM indication retains some current use, particularly with penicillin allergy
• Adult respiratory infections where second-generation cephalosporin spectrum matches need

Acute otitis media (AOM) is historically one of the most important cefaclor indications, particularly in pediatric practice during the 1980s and 1990s. The framework for contemporary AOM management comes from the American Academy of Pediatrics Clinical Practice Guideline for the Diagnosis and Management of Acute Otitis Media led by Lieberthal and colleagues (Pediatrics 2013;131:e964-e999), which positions amoxicillin as first-line with cefaclor and other cephalosporins as alternatives.

AOM pathogens and cefaclor activity:

🦠 Streptococcus pneumoniae (40-50% of cases)

Principal AOM pathogen. Cefaclor susceptibility variable; some pneumococcal strains with reduced penicillin susceptibility may also have reduced cefaclor susceptibility. High-dose amoxicillin generally preferred over cefaclor for empirical AOM.

🦠 Haemophilus influenzae (20-30% of cases)

Second most common AOM pathogen. Cefaclor reliable for non-beta-lactamase-producing strains; less reliable for beta-lactamase-positive strains (approximately 30-40% of H. influenzae in some regions). Augmentin or cefuroxime axetil generally preferred for confirmed H. influenzae.

🦠 Moraxella catarrhalis (5-10% of cases)

Common in younger pediatric AOM. Cefaclor reliable for non-beta-lactamase strains.

🦠 Streptococcus pyogenes (occasional)

Universally susceptible to cefaclor and all cephalosporins.

Cefaclor positioning in AOM:

Cefaclor dose for AOM:

Practical clinical workflow for AOM with cefaclor:

1. Confirm AOM diagnosis: tympanic membrane bulging, severely impaired mobility, or otorrhea (not just middle ear effusion alone)
2. Apply observation criteria (watchful waiting) per AAP - certain age groups with non-severe symptoms can be observed 48-72 hours before antibiotic initiation
3. Determine antibiotic appropriateness based on age, severity, prior treatment
4. For non-allergic patient without recent amoxicillin: high-dose amoxicillin first-line
5. For penicillin allergy or recent amoxicillin: cefaclor or other cephalosporin appropriate alternative
6. Pediatric dose: 20-40 mg/kg/day cefaclor divided t.i.d. for 10 days
7. Adult dose: 250-500 mg cefaclor t.i.d. for 10 days
8. Counsel about: GI tolerability, complete the course, return if no improvement at 48-72 hours, watch for serum sickness-like reaction
9. Follow-up at 48-72 hours if no improvement
10. For treatment failure: switch to alternative agent per Lieberthal guideline (Augmentin, cefdinir, ceftriaxone IM)
11. Document diagnosis criteria, allergy history, antibiotic choice rationale, follow-up plan

Acute bacterial sinusitis is a long-standing FDA-approved indication for cefaclor and remains an appropriate option for selected patients. The contemporary framework comes from the IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis (Chow et al, Clinical Infectious Diseases 2012) for adults and the AAP Clinical Practice Guideline for Pediatric Sinusitis (Wald et al, Pediatrics 2013) for children. Both guidelines position amoxicillin-clavulanate (Augmentin) as first-line with cefaclor and other cephalosporins as alternatives.

Sinusitis pathogens and cefaclor activity:

🦠 Streptococcus pneumoniae (30-40% of bacterial cases)

Susceptible to cefaclor in most regions; resistance rising in some areas. High-dose Augmentin generally preferred for empirical sinusitis where pneumococcal coverage is critical.

🦠 Haemophilus influenzae (20-35% of bacterial cases)

Cefaclor reliable for non-beta-lactamase strains; variable for beta-lactamase-positive strains. Augmentin covers beta-lactamase-positive H. influenzae more reliably.

🦠 Moraxella catarrhalis (5-10% of bacterial cases)

Cefaclor adequate for non-beta-lactamase strains.

🦠 Staphylococcus aureus (uncommon)

MSSA susceptible; MRSA resistant.

Cefaclor positioning in sinusitis:

Practical workflow for sinusitis with cefaclor:

1. Confirm bacterial sinusitis diagnosis: symptoms over 10 days OR severe initial symptoms with high fever and purulent discharge OR "double sickening"
2. Distinguish from viral rhinosinusitis (most cases under 10 days are viral)
3. Assess for penicillin allergy or contraindications to first-line Augmentin
4. If first-line not contraindicated: Augmentin 875/125 mg b.i.d. (adult) or 45 mg/kg/day amox component (pediatric) preferred
5. If penicillin allergy or other reason: cefaclor 500 mg t.i.d. (adult) or 20-40 mg/kg/day (pediatric) for 10 days
6. Consider local resistance patterns - cefuroxime axetil may be preferred over cefaclor where H. influenzae beta-lactamase rates are high
7. Counsel about GI tolerability, completion of course, serum sickness-like reaction watch
8. Follow-up if no improvement at 48-72 hours, worsening symptoms, severe headache, vision changes, or systemic symptoms
9. Document indication confirmation, antibiotic choice rationale, follow-up plan

Cefaclor is FDA-approved for lower respiratory tract infections including community-acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB). However, contemporary positioning has shifted: cefaclor is no longer a first-line empirical choice for most LRTI but retains a role in specific scenarios. Understanding the changing landscape supports appropriate selection.

Community-acquired pneumonia (CAP):

Why cefaclor has been displaced from first-line CAP:

• No atypical pathogen coverage - cefaclor does NOT cover Mycoplasma, Chlamydia, Legionella (10-25% of CAP). Macrolide or doxycycline needed for atypical coverage.
• Pneumococcal coverage adequate but not optimal - high-dose amoxicillin or respiratory fluoroquinolone preferred for pneumococcus
• Beta-lactamase-positive H. influenzae limitation
• Three-times-daily dosing inconvenient vs once-daily azithromycin or twice-daily Augmentin
• Newer agents with comparable efficacy and better adherence profiles

When cefaclor may still be appropriate for CAP:

• Penicillin-allergic patient where macrolide is unsuitable (drug interactions, resistance, etc)
• Documented susceptible bacterial pneumonia (not atypical)
• Specific patient factors favouring cephalosporin therapy

Acute exacerbations of chronic bronchitis (AECB):

AECB pathogens and cefaclor activity:

Haemophilus influenzae (30-50%)

Most common AECB pathogen. Cefaclor reliable for non-beta-lactamase strains.

Moraxella catarrhalis (15-25%)

Reliable cefaclor coverage.

Streptococcus pneumoniae

Reliable cefaclor coverage for susceptible strains.

Pseudomonas aeruginosa (advanced COPD)

Cefaclor does NOT cover Pseudomonas - patients with severe COPD, frequent exacerbations, or recent broad-spectrum exposure need anti-Pseudomonal coverage (fluoroquinolones or other classes).

Cefaclor dose for LRTI:

Practical workflow for LRTI with cefaclor:

1. Confirm bacterial LRTI diagnosis (CAP: clinical + radiographic; AECB: Anthonisen criteria)
2. Assess severity - mild/moderate appropriate for outpatient management
3. For CAP: standard first-line is amoxicillin, doxycycline, or macrolide - cefaclor not typically first choice
4. For AECB: Augmentin first-line; cefaclor appropriate alternative if Augmentin unsuitable
5. Review drug interactions (cefaclor has minimal CYP450 interaction concerns)
6. Consider risk factors for Pseudomonas in AECB (severe COPD, frequent exacerbations)
7. Counsel about: GI tolerability, complete the course, serum sickness-like reaction watch
8. Follow-up at 48-72 hours; reassess if no improvement
9. Document indication, regimen, follow-up plan

Streptococcal pharyngitis (Group A streptococcal pharyngitis, "strep throat") is an FDA-approved indication for cefaclor in the specific context of penicillin allergy. For non-allergic patients, penicillin V or amoxicillin remains the universal first-line treatment per the IDSA Clinical Practice Guideline (Shulman et al, Clinical Infectious Diseases 2012;55:e86-e102). Cefaclor and other cephalosporins are appropriate alternatives for penicillin-allergic patients.

Treatment hierarchy for Group A streptococcal pharyngitis:

💊 First-line: Penicillin V or amoxicillin (non-allergic)

Penicillin V 500 mg twice or three times daily for 10 days; OR amoxicillin 500 mg twice daily or 1000 mg once daily for 10 days; Pediatric: 50 mg/kg/day divided BID for 10 days. Reliable rheumatic fever prevention.

💡 Non-severe penicillin allergy (rash only): First-generation cephalosporin

Cephalexin 500 mg twice daily for 10 days; OR cefadroxil; OR cefuroxime axetil. First-generation cephalosporins have minimal cross-reactivity with penicillin in non-severe allergy.

💊 Non-severe penicillin allergy: Second-generation cephalosporin (cefaclor)

Cefaclor 250 mg three times daily for 10 days (adult); 20 mg/kg/day divided t.i.d. for 10 days (pediatric). Cefaclor is an appropriate alternative; cefuroxime axetil and cephalexin are also acceptable.

💊 Severe penicillin allergy (anaphylaxis, SJS, TEN): Non-beta-lactam

Clindamycin 300 mg three times daily for 10 days; OR clarithromycin/azithromycin (where macrolide resistance allows). Cefaclor and other cephalosporins are NOT appropriate for severe penicillin allergy due to potential cross-reactivity.

Why cefaclor 250 mg rather than higher dose for pharyngitis:

Group A streptococcus MIC for cefaclor is very low (typically under 0.5 mcg/mL when susceptible). The 250 mg three-times-daily dose produces tonsillar tissue concentrations far exceeding MIC for the full dosing interval. Higher doses (500 mg t.i.d.) do not add efficacy and increase adverse effect burden. The 10-day duration is essential for reliable streptococcal eradication and rheumatic fever prevention.

Macrolide resistance consideration for Group A strep:

In regions where macrolide resistance is high in Group A streptococcus (over 15%), cephalosporins including cefaclor are preferred over macrolides as the alternative to penicillin. Cefaclor remains reliable for Group A strep even where macrolide resistance is significant.

Practical workflow for Group A streptococcal pharyngitis:

1. Confirm Group A streptococcus diagnosis with rapid antigen test or throat culture (do not treat viral pharyngitis)
2. Review penicillin allergy history - clarify severity
3. Non-allergic patient: penicillin V or amoxicillin first-line for 10 days
4. Non-severe penicillin allergy (rash): cephalexin or cefaclor 250 mg t.i.d. for 10 days
5. Severe penicillin allergy: avoid cefaclor; use clindamycin or macrolide
6. Pediatric dose: weight-based (50 mg/kg/day amox for non-allergic; 20 mg/kg/day cefaclor t.i.d. for allergic)
7. Counsel about: complete full 10-day course (essential for rheumatic fever prevention), serum sickness-like reaction watch with cefaclor
8. Follow-up if symptoms persist beyond 48-72 hours
9. Document indication, allergy assessment, antibiotic choice rationale

Cefaclor has an FDA-approved indication for urinary tract infections caused by susceptible organisms, primarily E. coli, Klebsiella, and Proteus mirabilis. However, contemporary UTI guidelines from IDSA position other agents as first-line (nitrofurantoin, TMP-SMX, fosfomycin) with cefaclor and other oral cephalosporins as alternatives. Understanding the contemporary positioning supports appropriate empirical selection.

Cefaclor positioning in UTI:

Cefaclor dose for UTI:

Practical workflow for UTI with cefaclor:

1. Confirm UTI diagnosis (dysuria, frequency, urgency; consider urinalysis or culture per clinical context)
2. Distinguish uncomplicated from complicated UTI (catheter, structural abnormality, men, pregnancy, immunocompromised, etc)
3. Review local E. coli resistance to first-line agents (nitrofurantoin, TMP-SMX)
4. For uncomplicated cystitis: first-line agents generally preferred over cefaclor
5. If cefaclor appropriate: 250 mg t.i.d. for 7 days (uncomplicated); higher dose and longer duration for complicated
6. Counsel about completing course, hydration, return if symptoms persist
7. Document indication, antibiotic choice rationale

Cefaclor is FDA-approved for skin and soft tissue infections caused by Staphylococcus aureus and Streptococcus pyogenes. However, in contemporary practice, cephalexin (first-generation) is generally preferred for typical SSTI given equivalent gram-positive coverage and simpler dosing. Cefaclor retains a role for selected scenarios.

SSTI pathogens and cefaclor activity:

🦠 Methicillin-sensitive Staphylococcus aureus (MSSA)

Most common SSTI pathogen. Reliable cefaclor coverage.

🦠 Streptococcus pyogenes (Group A streptococcus)

Common cellulitis pathogen. Universally cefaclor-susceptible.

🦠 MRSA (methicillin-resistant S. aureus)

NOT covered by cefaclor. For purulent SSTI or risk factors for MRSA, alternative agents needed (TMP-SMX, doxycycline, clindamycin).

🦠 Anaerobes (cellulitis from bites, diabetic foot)

Cefaclor has limited anaerobic activity. For bite wounds or diabetic foot infections, Augmentin or alternative agents preferred.

SSTI treatment hierarchy:

Cefaclor dose for SSTI:

Practical workflow for SSTI with cefaclor:

1. Confirm SSTI diagnosis and assess severity
2. Distinguish purulent (suspect MRSA) from non-purulent (likely streptococcal/MSSA)
3. Check for risk factors for resistant organisms (recent hospitalisation, IV drug use, diabetes, etc)
4. For non-purulent mild cellulitis (likely streptococcal): cephalexin or cefaclor both appropriate
5. For purulent SSTI with MRSA risk: AVOID cefaclor - use MRSA-active agent
6. For bite wounds or diabetic foot: AVOID cefaclor - use Augmentin or alternative with anaerobic coverage
7. Counsel about wound care, complete the course, return if worsening
8. Document indication, choice rationale, follow-up plan

Standard adult cefaclor dosing is 250-500 mg three times daily for immediate-release, or 375-500 mg twice daily for Ceclor CD extended-release. The dose and duration vary by indication. The standard t.i.d. dosing of immediate-release reflects the short half-life and time-above-MIC pharmacodynamic requirement.

Adult cefaclor dosing by indication:

Practical administration considerations:

Immediate-release timing

Take on empty stomach (1 hour before or 2 hours after meals) for optimal absorption. Take with food if GI upset develops (small bioavailability decrease is acceptable trade-off).

Ceclor CD timing

Take with food. Food improves CD absorption. Swallow whole - do not crush, split, or chew.

Dose spacing

For t.i.d.: every 8 hours (e.g., 8 AM, 4 PM, midnight). For b.i.d.: every 12 hours (e.g., 8 AM, 8 PM). Spacing matters for time-above-MIC.

Hydration

Maintain adequate fluid intake (1.5-2 L daily) during therapy.

Complete the course

Critical for streptococcal pharyngitis (rheumatic fever prevention) and to prevent resistance emergence.

Practical workflow for adult cefaclor prescribing:

1. Confirm appropriate indication for cefaclor
2. Review patient drug interactions (cefaclor has favorable profile compared to clarithromycin; review warfarin, oral contraceptives)
3. Review allergy history (penicillin allergy severity)
4. Review renal function (eCrCl) - dose adjust below 30
5. Choose formulation: IR (more dosing flexibility) or CD (adherence advantage)
6. Prescribe dose by indication from table above
7. Counsel about: dosing schedule, food timing (IR empty stomach; CD with food), complete course, common adverse effects, serum sickness-like reaction watch
8. Plan follow-up appropriate to indication
9. Document indication, dose, duration, drug interaction review

Pediatric cefaclor dosing is weight-based and one of the historical strengths of Ceclor compared to other antibiotics. The combination is FDA-approved for children 1 month of age and older. The standard pediatric dose is 20-40 mg/kg/day divided three times daily for most indications, with maximum 1 gram per day.

Pediatric cefaclor dosing by indication:

Pediatric-specific clinical considerations:

Age 1 month to under 6 months

FDA-approved but less commonly used; pediatric ID input appropriate for serious infections in this age range. Consider whether the indication truly requires cefaclor vs alternatives.

Age 6 months to 12 years

Standard pediatric use; suspension is dominant formulation. Calculate weight-based dose carefully and verify with caregivers.

Adolescents and older children

Can transition to capsules when able to swallow. Adult dosing applies for adolescents over 40 kg.

Serum sickness-like reaction

Distinctive cefaclor concern more common in pediatric patients. Counsel caregivers explicitly about warning signs (joint pain, rash, fever 1-3 weeks after starting). See Section 23.

Renal function

Use weight-based eGFR estimation for pediatric dose adjustment if needed. Significant pediatric renal impairment is uncommon but warrants attention.

Pediatric workflow:

1. Confirm appropriate pediatric indication (AOM, sinusitis, pharyngitis, SSTI, UTI)
2. Confirm age 1 month or older
3. Calculate weight-based dose: 20-40 mg/kg/day per indication; verify max 1 g/day
4. Select suspension strength for practical mL per dose
5. Counsel caregivers on administration (oral syringe, complete course, shake suspension)
6. Discuss serum sickness-like reaction warning signs explicitly
7. Discuss GI tolerability and common AEs
8. Plan follow-up 48-72 hours if clinical response uncertain
9. Document weight, dose, indication, counselling

Cefaclor oral suspension is the dominant pediatric formulation and one of the practical strengths of the Ceclor product family. The suspension is available in multiple strengths (125, 187, 250, 375 mg per 5 mL) supporting flexible weight-based dosing. Proper reconstitution, storage, and administration are essential for therapeutic effect.

Available suspension strengths:

Reconstitution and preparation:

Pharmacist preparation

Cefaclor suspension is reconstituted by the pharmacist at the time of dispensing. Dry granules are mixed with water in specified amount to produce ready-to-use suspension.

Final volume

Reconstituted suspension volume varies by strength and bottle size (typical 50, 75, 100, or 150 mL). Verify the volume matches expected dose-day calculation for the prescribed course.

Mixing

The pharmacist shakes vigorously after adding water to ensure uniform suspension. Resuspension should be smooth without obvious lumps.

Storage of reconstituted suspension:

Administration to children:

Shake well before each dose

Vigorously shake the bottle to ensure uniform drug distribution. Suspended particles can settle during storage.

Measure accurately

Use the dosing syringe or measuring cup provided by the pharmacy. Do NOT use household teaspoons - they vary by 50-100% in volume and are unsafe for medication dosing.

Administer to child

Oral syringe is preferred for infants and young children - allows accurate small-volume dosing. Aim syringe toward cheek (not back of throat) to prevent gagging or aspiration.

Pair with routine

Pair dosing with consistent daily activities (meals, before/after specific tasks) to support adherence.

Complete the course

Essential for streptococcal pharyngitis (rheumatic fever prevention) and to prevent resistance.

Common suspension mistakes:

• Not refrigerating - cefaclor suspension MUST be refrigerated (different from many other antibiotic suspensions)
• Using household teaspoons - unreliable measurement; use the provided syringe or measuring cup
• Not shaking well - drug particles settle; uneven dosing results
• Mixing into full meals - if child does not finish meal, full dose not delivered
• Storing too long - 14 days is the maximum; discard older suspension
• Reusing bottles for different prescriptions - always use fresh bottle for new course

Cefaclor is predominantly renally cleared - approximately 60-85% of an oral dose appears in urine as unchanged drug within 8 hours. In significant renal impairment, cefaclor accumulates, with extended half-life and increased risk of adverse effects. Dose reduction is required at eCrCl below 30 mL/min.

Renal function thresholds for cefaclor dosing:

Pharmacokinetic basis for renal adjustment:

Cefaclor renal clearance

60-85% of dose excreted unchanged in urine. Both glomerular filtration and tubular secretion contribute. With reduced renal function, clearance falls proportionally.

Half-life extension in renal impairment

Normal half-life 0.6-0.9 hours. In severe renal impairment (eCrCl below 10), half-life can extend to 3-5 hours. This affects steady-state accumulation and dose interval considerations.

Adverse effect risk

Accumulated drug increases risk of GI adverse effects, hypersensitivity reactions, and rare hematologic effects. Renal dose reduction prevents excessive exposure.

Hemodialysis considerations

Cefaclor is removed by hemodialysis. For dialysis patients, supplemental dose after dialysis is generally not required but may be considered for severe infections. Ceclor CD is generally not preferred in dialysis patients due to dosing inflexibility.

Special pediatric renal considerations:

• Use weight-based eGFR estimation (Schwartz formula) for pediatric renal assessment
• Significant pediatric renal impairment is uncommon but warrants attention
• Reduce pediatric dose proportionally if eGFR below 50 mL/min/1.73 m squared
• Pediatric ID/nephrology consultation appropriate for complex cases

Cefaclor has a favourable hepatic profile compared to many other antibiotics - the drug is not significantly metabolised by the liver and rare hepatic adverse effects occur. Cefaclor does not require significant dose adjustment in hepatic impairment (unlike clarithromycin or other heavily-metabolised agents). However, some monitoring considerations apply for patients with pre-existing liver disease.

Hepatic considerations summary:

Mild to moderate hepatic impairment

No dose adjustment needed. Standard cefaclor dosing appropriate.

Severe hepatic impairment

Generally no specific dose adjustment for cefaclor alone. However, if patient also has renal impairment (common in severe hepatic disease), renal-based dose adjustment applies.

Combined hepatic + renal impairment

Renal dose adjustment based on eCrCl is the principal consideration. Hepatic component does not require additional reduction.

Pre-existing liver disease

No specific cefaclor contraindication. Monitor liver function during prolonged therapy as for any antibiotic.

Rare hepatic adverse effects (uncommon):

Warning signs of hepatic adverse effects:

• Unexplained nausea, vomiting, fatigue
• Jaundice (yellow skin or eyes)
• Dark urine
• Right upper quadrant pain
• Pruritus (itching) without other explanation

Monitoring recommendations:

• Routine short-course therapy (7-14 days): no routine liver function monitoring needed for healthy patients
• Pre-existing liver disease: consider baseline LFTs if extended course planned
• Concurrent hepatotoxic medications: more cautious monitoring
• Symptoms of hepatic adverse effect: immediate LFT evaluation

Cefaclor has a favourable drug interaction profile compared to many other antibiotics. The drug is minimally metabolised (no significant CYP450 involvement) and primarily renally excreted. This means cefaclor does NOT have the substantial drug interaction burden of macrolides like clarithromycin (which strongly inhibits CYP3A4). However, several clinically relevant interactions warrant attention.

Clinically relevant cefaclor interactions:

What cefaclor does NOT significantly interact with:

• Statins - no significant CYP3A4 interaction (unlike clarithromycin)
• Direct oral anticoagulants (DOAC) apixaban, rivaroxaban - no significant interaction (though warfarin requires monitoring)
• Calcium channel blockers - no significant interaction
• Immunosuppressants (tacrolimus, cyclosporine) - no significant CYP3A4 interaction
• Antiretroviral therapy - minimal interactions; check specific agents
• Benzodiazepines - no significant interaction
• SSRI/SNRI antidepressants - no significant interaction
• QT-prolonging medications - cefaclor does not significantly prolong QT

Practical interaction management:

1. Review patient medication list at cefaclor prescription
2. Identify warfarin use - plan INR monitoring during therapy
3. Identify probenecid - consider alternative or dose adjustment
4. For oral contraceptive users: counsel about backup contraception (conservative recommendation)
5. For patients on aminoglycosides or loop diuretics with renal concerns: monitor renal function
6. For patients on antacids: space dosing appropriately
7. Document interaction screening review

Cefaclor has a favourable pregnancy and lactation safety profile based on decades of clinical experience. The drug is classified as Pregnancy Category B (under the historical FDA classification system) - animal reproduction studies have not demonstrated risk and there are no adequate well-controlled studies in pregnant women, but human exposure data is generally reassuring. Cefaclor is among the antibiotics considered acceptable for use during pregnancy when indicated.

Trimester-specific considerations:

First trimester (weeks 1-13)

Acceptable for use when indicated. Decades of clinical experience without significant teratogenicity signal. The pregnancy-related antibiotic safety hierarchy generally places cephalosporins (including cefaclor) among the safer choices.

Second trimester (weeks 14-27)

Acceptable for use when indicated. Same safety profile as first trimester.

Third trimester (weeks 28-40)

Acceptable for use when indicated. No specific late-pregnancy concerns. Standard precautions apply.

Lactation (postpartum)

Cefaclor is excreted in breast milk in small amounts (under 1% of maternal dose). Generally compatible with breastfeeding (LactMed L2). Monitor breastfed infant for GI symptoms (diarrhoea), thrush, or rash. Most infants tolerate maternal cefaclor without adverse effects.

Specific clinical scenarios in pregnancy:

Patient counselling for pregnant/lactating patients:

• Cefaclor has a favourable pregnancy safety profile based on decades of experience
• Used when indicated for bacterial infections during pregnancy
• Generally compatible with breastfeeding; monitor infant for GI symptoms
• Complete the prescribed course unless severe adverse effects
• Standard counselling about adverse effects, drug interactions applies
• Document indication, pregnancy/lactation discussion, treatment plan

Cefaclor is generally well-tolerated with adverse effects similar to other oral cephalosporins. The most common adverse effects are gastrointestinal (mild nausea, diarrhoea, abdominal discomfort). Cefaclor has one distinctive adverse effect that warrants special attention: the serum sickness-like reaction (covered in detail in Section 23). Most common effects are mild and resolve without specific intervention.

Tolerability overview:

GI adverse effects management:

Mild diarrhoea

Often related to gut microbiota disruption from beta-lactam therapy. Encourage hydration; usually self-limiting and resolves with completion of therapy. Probiotics may help in some patients.

Nausea and abdominal discomfort

Taking immediate-release cefaclor with food may reduce GI upset (slight bioavailability decrease is acceptable trade-off). Ceclor CD requires food anyway.

Severe persistent diarrhoea

Concerning for C. difficile colitis. Watery diarrhoea, abdominal cramping, or fever during/after therapy warrants evaluation.

Vomiting

Less common; usually mild. If significant, consider whether alternative agent or formulation appropriate. Vomiting may also compromise absorption.

Dermatologic adverse effects:

Mild rash

Maculopapular rash; commonly during the second week of therapy. Mild rash often resolves without discontinuation, but evaluation appropriate to distinguish from more serious reactions.

Urticaria

Hive-like reaction; may indicate hypersensitivity. Consider discontinuation and alternative agent.

Pruritus

Itching with or without rash. Mild and isolated cases may not require intervention; more severe pruritus or with mucosal involvement warrants evaluation.

Patient counselling for common adverse effects:

• Expect mild GI effects (diarrhoea, nausea); generally not dangerous
• Take immediate-release with or without food (with food reduces GI upset slightly)
• Take Ceclor CD with food (required for absorption)
• Maintain hydration during therapy
• Complete the prescribed course unless severe adverse effects
• Watch for serum sickness-like reaction (joint pain, rash, fever) within 1-3 weeks of starting cefaclor - see Section 23
• Contact prescriber for: severe persistent diarrhoea, fever with rash, severe abdominal pain, joint swelling, severe rash, difficulty breathing
• For pediatric patients: caregivers should observe for late reactions even after course completion

Comparison to other antibiotics:

The practical tolerability message for cefaclor: generally well-tolerated for most patients with mild side effects. The distinctive concern requiring patient counselling is the serum sickness-like reaction. Routine GI effects are manageable. Complete the course unless serious adverse effects develop.

The serum sickness-like reaction is a distinctive adverse effect associated specifically with cefaclor - more so than with other cephalosporins. The reaction was first recognised in the 1980s through pediatric case series and surveillance reports. It is uncommon (frequency under 0.5%) but warrants explicit patient counselling because: (1) it can be alarming for patients and caregivers, (2) recognition matters for prompt discontinuation, and (3) the reaction is particularly associated with pediatric cefaclor use.

What is serum sickness-like reaction?

Clinical presentation

Triad of symptoms: joint pain or swelling (arthralgia/arthritis), skin rash (urticaria or erythema), and fever. Additional features may include lymphadenopathy, malaise, and rarely visceral involvement.

Timing

Typically develops 1-3 weeks after starting cefaclor (median 7-10 days). Can occur even after the course is completed. The delayed onset distinguishes from typical immediate hypersensitivity reactions.

Mechanism

Type III hypersensitivity (immune complex deposition) is thought to be involved, though the mechanism is not fully understood. Cefaclor metabolites may form immune complexes with antibodies, depositing in joints and skin to produce symptoms.

Differentiation from true serum sickness

"Serum sickness-LIKE" emphasises the clinical similarity to classical serum sickness without identical immunological features. Complement levels and renal involvement (typical of true serum sickness) are usually absent.

Resolution

Symptoms typically resolve within 1-2 weeks after discontinuing cefaclor. Most cases resolve completely without long-term consequences.

Warning signs for patients and caregivers:

Management of serum sickness-like reaction:

Discontinue cefaclor immediately

Stop the antibiotic at first recognition of the reaction. Do not continue the course "to see if it passes." Discontinuation is essential for resolution.

Supportive care

Antipyretics for fever (acetaminophen typically). Antihistamines for urticarial symptoms. NSAIDs for joint pain in adults (use caution in children). Adequate hydration.

Corticosteroids

Reserved for moderate to severe cases - oral prednisone short course can speed resolution of symptoms. Most mild cases resolve without corticosteroids.

Medical evaluation

Evaluation appropriate to characterise the reaction, distinguish from more serious conditions, and document the adverse drug reaction.

Future cefaclor avoidance

Patient should avoid cefaclor in future. Cross-reactivity with other cephalosporins is uncommon but conservative practice avoids related agents and uses non-cephalosporin alternatives going forward.

Pediatric particular concern:

Serum sickness-like reaction appears more common in pediatric patients receiving cefaclor than in adults. The reasons are not fully understood but may relate to immune system features at different developmental stages. The reaction has been reported in children receiving cefaclor for routine indications like otitis media. This is one of the considerations that has narrowed cefaclor pediatric use compared to its peak in the 1990s.

Frequency perspective:

• Population frequency: approximately 0.024-0.5% of cefaclor courses
• Higher in pediatric than adult populations
• Higher in repeated cefaclor exposures than first courses
• Most patients will NOT experience serum sickness-like reaction
• Awareness and prompt recognition prevents prolonged distress when reaction does occur

While cefaclor is generally well-tolerated, several rare but serious adverse reactions warrant awareness for safe prescribing. Severe reactions are uncommon (typically under 1% frequency) but recognition matters because early identification and discontinuation reduces severity and improves outcomes.

Major severe adverse reactions:

Risk perspective:

For most patients prescribed short-course (7-14 day) cefaclor, severe adverse reactions are very uncommon. The risk-benefit balance strongly favours antibiotic therapy when the indication is appropriate. Awareness of severe reactions matters because prompt recognition saves lives. The serum sickness-like reaction is the most notable cefaclor-specific concern requiring counselling at every prescription.

Penicillin-cephalosporin cross-reactivity is one of the most discussed antibiotic allergy topics in clinical practice. Historical estimates suggested 10% cross-reactivity but contemporary evidence has substantially revised this estimate downward. For cefaclor specifically (and second-generation cephalosporins generally), cross-reactivity with penicillin allergy is much lower than the historical figure - allowing cefaclor use in many patients with non-severe penicillin allergy.

Penicillin allergy severity stratification for cefaclor decision:

Clarifying patient penicillin allergy history:

What to ask

"What happened when you took penicillin?" Get specific details: type of reaction, timing after dose, severity, treatment needed, hospitalisation, how long ago. Many "penicillin allergies" are vague history without specific reaction details.

Common misattributions

Many patients label "penicillin allergic" for: GI upset (not actually allergy), childhood rash that resolved (often not penicillin-related), family history of penicillin allergy (not patient personal allergy), vague unease about penicillin without specific reaction.

True severe allergy

Anaphylaxis, hives requiring epinephrine, SJS/TEN, DRESS syndrome - these are true severe allergies that warrant avoiding cephalosporins.

Allergy testing

For complex cases, allergy testing (skin testing, drug challenge under supervision) can clarify true allergy status. Many "penicillin allergic" patients found on testing to not actually be allergic - allowing safer broader antibiotic options.

Practical workflow for cefaclor in penicillin-allergic patients:

1. Get specific penicillin allergy history - what happened, when, how severe
2. Categorise: non-severe, moderate, or severe based on details
3. For non-severe allergy: cefaclor acceptable; counsel about low residual risk
4. For moderate allergy: consider non-beta-lactam alternatives; cefaclor possible with caution
5. For severe allergy: AVOID cefaclor; use non-cephalosporin alternative
6. For unclear history: more cautious choice initially; consider allergy referral for future clarification
7. Document allergy assessment, decision rationale, and any counselling provided
8. If reaction occurs: stop immediately, treat as needed, document for future reference

Cefaclor susceptibility patterns have evolved over its four decades of clinical use. The principal resistance concerns for cefaclor are beta-lactamase production (especially in H. influenzae), pneumococcal penicillin resistance (often associated with reduced cephalosporin susceptibility), and broader Enterobacterales resistance (ESBL producers). Understanding contemporary resistance patterns supports appropriate empirical use.

Resistance mechanisms affecting cefaclor:

Beta-lactamase production

Bacteria produce enzymes (beta-lactamases) that hydrolyse the beta-lactam ring, inactivating cefaclor. Cefaclor has moderate beta-lactamase stability - better than first-generation cephalosporins but less than cefuroxime axetil among second-generation. Beta-lactamase-positive H. influenzae and M. catarrhalis are common contributors to cefaclor failure in respiratory infections.

Altered penicillin-binding proteins (PBPs)

Pneumococcal resistance to cephalosporins often involves altered PBPs with reduced binding affinity. Pneumococcus with reduced penicillin susceptibility (PRSP) frequently has reduced cefaclor susceptibility too. High pneumococcal cephalosporin resistance regions affect cefaclor empirical reliability.

Extended-spectrum beta-lactamases (ESBL)

Enterobacterales producing ESBLs hydrolyse most cephalosporins including cefaclor. ESBL prevalence varies regionally; in healthcare-exposed patients or specific geographic areas, ESBL E. coli and Klebsiella have substantial prevalence.

Efflux and porin changes

Some gram-negative organisms have membrane changes affecting cefaclor uptake. Less common cause of resistance but contributes to resistance patterns.

Contemporary resistance rates for cefaclor targets:

Stewardship implications for cefaclor:

• Use cefaclor where its spectrum genuinely matches the suspected pathogens and local resistance is acceptable
• For empirical respiratory infections where beta-lactamase-positive H. influenzae is likely: Augmentin or cefuroxime axetil generally preferred over cefaclor
• For confirmed susceptible pathogens (Group A strep, susceptible S. pneumoniae): cefaclor remains appropriate
• Review local antibiogram before empirical use in high-resistance regions
• Document indication and antibiotic choice rationale
• Complete prescribed courses - incomplete courses drive resistance

Amoxicillin and cefaclor are both commonly used oral antibiotics for community-acquired bacterial infections in adults and children. Both are beta-lactam antibiotics with similar mechanisms but distinct spectra, drug interaction profiles, and clinical positioning. Understanding the comparison clarifies when each is appropriate.

Head-to-head comparison:

Indication-specific preference:

Pharmacokinetic comparison:

Amoxicillin-clavulanate (Augmentin) is amoxicillin combined with the beta-lactamase inhibitor clavulanate. The combination provides extended coverage of beta-lactamase-producing organisms that escape both amoxicillin and cefaclor. Augmentin has become first-line for many indications previously served by cefaclor (sinusitis, AECB, otitis media in selected scenarios).

Head-to-head comparison:

Indication-specific preference:

Cephalexin (Keflex) is a first-generation oral cephalosporin and a common alternative to cefaclor for many indications. The choice between cephalexin (first-generation) and cefaclor (second-generation) depends on the specific clinical scenario - cephalexin is generally preferred for skin/soft tissue and UTI, while cefaclor offers broader gram-negative respiratory coverage.

Head-to-head comparison:

Indication-specific preference:

Adverse effect comparison:

Common adverse effects

Both cefaclor and cephalexin have similar mild GI adverse effect profiles. Both are generally well-tolerated.

Serum sickness-like reaction

Cefaclor distinctive concern - 0.024-0.5% incidence. Cephalexin has NO significant serum sickness-like reaction association. This is one of the practical advantages of cephalexin for routine pediatric use.

Severe reactions

Similar profiles for SCAR, C. difficile, anaphylaxis. Both first-generation and second-generation cephalosporins have generally favorable safety records.

Cefaclor is appropriate for specific indications and patient profiles but has clear limitations that make alternative antibiotics preferable in many clinical scenarios. Understanding when NOT to choose cefaclor prevents inappropriate prescribing and directs patients to better-matched therapy.

When to choose an alternative - clear decision points:

Specific alternative recommendations:

Stewardship-conscious approach:

1. Confirm the indication actually requires antibiotic therapy (many upper respiratory and bronchitis cases are viral)
2. Choose narrowest appropriate spectrum for likely pathogen
3. Consider patient-specific factors: allergies, renal function, drug interactions (cefaclor has favorable profile), prior antibiotics
4. Review local resistance patterns
5. For most non-allergic patients with respiratory infections: amoxicillin first-line
6. For penicillin-allergic patients: cefaclor (non-severe) or non-beta-lactam (severe)
7. Reserve cefaclor for indications where its specific properties match - penicillin allergy alternative, broader respiratory gram-negative coverage
8. Document indication-appropriate selection

Cefaclor storage requirements differ significantly between formulations - capsules at room temperature, reconstituted suspension under refrigeration. Following storage guidelines preserves drug potency and clinical effectiveness through the labelled expiration date.

Storage requirements by formulation:

Common storage mistakes to avoid:

Not refrigerating suspension

Common mistake especially with first-time pediatric prescriptions. Explicitly tell caregivers "Keep in the refrigerator" for cefaclor suspension - different from some other antibiotic suspensions they may have used.

Storing capsules in bathroom

Bathroom moisture and temperature fluctuations are not ideal. Store capsules in kitchen cabinet or bedroom drawer.

Saving leftover suspension

Reconstituted suspension cannot be saved beyond 14 days. Do not save partial bottles for future infections.

Mixing suspension with other liquids for storage

Suspension should be stored in its original bottle. Mixing with juice or other liquids changes stability and is not recommended.

Travel considerations:

• Capsules: Carry in original packaging in carry-on luggage; protect from heat extremes
• Suspension during travel: Use insulated cool packs to maintain refrigeration; plan around availability of refrigeration at destination
• Short trips (under a day): Suspension can be at room temperature for a few hours during travel; return to refrigeration as soon as practical
• International travel: Bring prescription documentation; consider whether capsules vs suspension is more practical for travel

Disposal:

• Best: Drug take-back programmes at pharmacies or designated collection events
• Acceptable: Mix unused medication with unpalatable substance (used coffee grounds, kitty litter), seal in container, dispose in household trash
• Do NOT flush down toilet - environmental antibiotic resistance pressure
• Do NOT share unused medication or save partial courses

Cefaclor missed dose handling depends on the formulation (three-times-daily IR vs twice-daily CD) and timing relative to the next scheduled dose. The short half-life of cefaclor means missed doses can produce significant gaps in antibacterial pressure - adherence matters.

General missed dose principle:

Specific guidance by formulation:

Immediate-release Ceclor (three-times-daily)

Dosing interval is 8 hours. If you remember within 4 hours of the missed dose time, take it. If more than 4 hours have passed (closer to next dose), skip it and continue normal schedule. The short half-life means brief missed doses create exposure gaps.

Ceclor CD extended-release (twice-daily)

Dosing interval is 12 hours. If you remember within 6 hours of the missed dose time, take it with food. If more than 6 hours have passed, skip it and continue. Remember Ceclor CD must be taken with food.

Pediatric suspension

Apply the same 8-hour interval rule as immediate-release capsules. If within 4 hours of missed dose time, give. If more than 4 hours, skip and continue normal schedule.

Multiple consecutive missed doses

If patient has missed several doses (e.g., a full day), contact prescriber for guidance. May need to restart timing or extend course depending on circumstances.

What NOT to do:

• Do NOT take double doses to "catch up" - increases adverse effect risk (especially GI)
• Do NOT crush or modify Ceclor CD tablets to compensate
• Do NOT take Ceclor CD without food just to make up for a missed dose
• Do NOT extend the course beyond what was prescribed
• Do NOT stop the course early because you missed several doses

Adherence support strategies:

• Set phone alarms for each dose time (especially three-times-daily IR)
• Pair with daily routines - meals work well (breakfast, lunch, dinner for TID)
• Pill organisers for weekly tracking of capsules
• Medication apps for adherence reminders
• Once-daily Ceclor CD for simpler schedule when indication allows
• Caregiver involvement for pediatric or cognitively impaired patients
• Travel preparation - bring medication and plan timing

Practical importance of completion:

Incomplete antibiotic courses drive resistance development and may produce treatment failure. For cefaclor specifically: streptococcal pharyngitis requires the full 10-day course for reliable Group A strep eradication and rheumatic fever prevention. Complete the prescribed course unless severe adverse effects warrant discontinuation under prescriber guidance.

Cefaclor use in older adults has a generally favorable profile compared to many other antibiotics. The favorable drug interaction profile (minimal CYP450 involvement), reasonable safety record, and oral cephalosporin spectrum make cefaclor an option in elderly patients. However, age-related renal decline and other considerations warrant attention.

Geriatric considerations for cefaclor:

Practical geriatric prescribing approach:

1. Calculate eGFR for every elderly patient
2. Review complete medication list including OTC products and supplements
3. Verify warfarin status - plan INR monitoring during cefaclor therapy
4. Assess swallowing - capsules vs suspension if difficulty
5. Choose dosing schedule appropriate to patient (TID IR or BID CD if applicable)
6. Counsel about: complete the course, warning signs (severe diarrhoea, joint pain, rash, allergy symptoms), warfarin INR monitoring if applicable
7. Plan follow-up appropriate to patient complexity
8. Document indication, dose, drug interaction review

Generic cefaclor has been available since the 1990s and is widely produced by multiple manufacturers globally. Generic cefaclor is bioequivalent to brand Ceclor with the same active ingredient, same dose strengths, same indications, and the same clinical effectiveness. Generic substitution is universal in most markets.

Cost comparison overview:

Actual prices vary by region, pharmacy, insurance coverage, and discount programmes.

Quality considerations for generic cefaclor:

FDA-approved generic standards

All US-marketed generic cefaclor must demonstrate bioequivalence to brand Ceclor through FDA-required studies. Approved generics are interchangeable.

Manufacturer variation

Multiple manufacturers produce generic cefaclor (Sandoz, Teva, Mylan, Sun Pharma, Cipla, others). Quality generally comparable among reputable manufacturers.

Suspension formulations

Generic suspensions are bioequivalent but may differ in flavouring. Patient preferences can guide selection between equivalent generics.

Ceclor CD generics

Generic extended-release cefaclor is available. FDA-approved generic CD formulations meet bioequivalence standards for the sustained-release profile.

Cost compared to alternatives:

Insurance and assistance:

• Most insurance plans cover generic cefaclor with low copayment
• Discount programmes (GoodRx, Cost Plus) often bring out-of-pocket cost to USD 5-20 for typical course
• Brand Ceclor may have higher copayment; substitute generic if covered
• Pediatric suspensions may have specific insurance coverage considerations

Global access considerations:

• Cephalosporins are on the WHO Essential Medicines List Access tier
• Generic cefaclor available in most countries worldwide
• Pricing varies dramatically by region
• Affordable enough to be accessible across diverse healthcare settings

Looking ahead from 2025-2030, cefaclor will likely retain a more focused but stable role in oral antibiotic prescribing. Several trends will shape the future positioning: continued resistance evolution, antimicrobial stewardship intensification, competition from other oral cephalosporins, and shifting first-line guidelines.

Key trends shaping the future:

Indications where cefaclor role likely preserved:

Penicillin-allergic patients with respiratory infections

Cefaclor remains useful for sinusitis, otitis media, AECB in penicillin-allergic patients where cephalosporin is acceptable alternative.

Streptococcal pharyngitis (penicillin-allergic)

Cephalosporins including cefaclor remain appropriate for non-severe penicillin-allergic patients.

Selected pediatric otitis media

Where amoxicillin has recently failed or in penicillin-allergic children.

Resource-limited settings

Where access to newer agents is limited, cefaclor remains a valuable oral cephalosporin option globally.

Indications where cefaclor role likely diminishes:

• First-line empirical for most pediatric AOM (amoxicillin preferred)
• First-line for acute bacterial sinusitis (Augmentin preferred)
• First-line empirical for SSTI (cephalexin preferred)
• First-line for CAP (amoxicillin/doxycycline/macrolide preferred)
• UTI (nitrofurantoin/TMP-SMX preferred where appropriate)
• Where alternative oral cephalosporins (cefdinir, cefpodoxime) provide once-daily convenience

Practical implications for current clinicians:

• Continue using cefaclor for indications where it remains appropriate per current guidelines
• Stay current with regional resistance epidemiology
• Review updated guidelines (IDSA, AAP) periodically
• Consider whether amoxicillin or Augmentin would be equally or more appropriate
• Reserve cefaclor for the specific scenarios where its properties (penicillin-allergic alternative, second-generation cephalosporin spectrum) justify selection
• Counsel patients about serum sickness-like reaction (distinctive cefaclor concern)
• Document indication-appropriate selection

The broader perspective is that cefaclor transitions from a peak-use oral antibiotic of the 1980s-1990s to a more thoughtfully-positioned agent in contemporary practice. The drug remains clinically important for specific scenarios; the broader empirical use has been ceded to other agents with better-matched profiles for specific indications. Generic availability ensures continued affordability and accessibility.

For the FDA-approved indications in appropriate patient profiles, cefaclor continues to provide a clinically valid, well-established oral cephalosporin option with a long safety record. The continued role is more focused than peak use but remains meaningful in community antibiotic practice.